Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Amgen
- 23 Mar 2020 Results summarizing malignancy rates in psoriasis clinical studies of brodalumab (NCT00975637; NCT01101100; NCT01708590 (AMAGINE-1); NCT01708603 (AMAGINE-2); NCT01708629 (AMAGINE-3).) published in the American Journal of Clinical Dermatology
- 05 Jun 2019 Results published in the Journal of the American Academy of Dermatology
- 03 Oct 2017 Results (n=4464) of exploratory analysis assessing psychiatric adverse events occurrence across late stage brodalumab patients using patient data from NCT00975637, NCT01101100, NCT01708590, NCT01708603 and NCT01708629 trials and their open label extensions published in the Journal of the American Academy of Dermatology